Actively Recruiting

Early Phase 1
Age: 18Years - 40Years
FEMALE
Healthy Volunteers
NCT05760144

Endometrial Biopsy in Progestin Contraceptive Users

Led by Oregon Health and Science University · Updated on 2025-03-20

52

Participants Needed

1

Research Sites

174 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to learn more about menstrual changes in progestin contraception users. The investigators are hoping to find out what changes in the endometrium lead to different bleeding patterns during the first year of progestin contraception use. Participants will choose to receive the contraceptive implant (Etonogestrel implant also called Nexplanon) or the contraceptive injectable (Depo-medroxyprogesterone acetate (DMPA) also called Depo-Provera) for up to 12 months. They will be asked to have 4 endometrial biopsies over the course of the study, as well as blood draws, physical exams, and pregnancy tests. Participants will also use a daily text message or email diary to report bleeding patterns. This study's plan is to comprehensively phenotype bleeding patterns and profile the entire endometrium using single-cell RNA seq data (sCRNAseq).

CONDITIONS

Official Title

Endometrial Biopsy in Progestin Contraceptive Users

Who Can Participate

Age: 18Years - 40Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Female, 18 to 40 years old, in good general health at enrollment
  • Regular menstrual cycles (25-35 days) with bleeding lasting 8 days or less
  • Body Mass Index between 19 and 35
  • Confirmed ovulation indicated by serum progesterone greater than 3 ng/mL
  • No medical reasons preventing use of Depo-Provera or contraceptive implant
Not Eligible

You will not qualify if you...

  • Use of hormonal or intrauterine contraceptives or hormones within specified washout periods before enrollment
  • Known uterine diseases such as endometriosis, fibroids, adenomyosis, or infections
  • Positive test for gonorrhea or chlamydia at screening unless treated
  • Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) 14 or more days per month
  • Abnormal uterine bleeding or polycystic ovary syndrome
  • Currently pregnant or planning pregnancy during the study
  • Less than 6 months postpartum, breastfeeding, or recent abortion within specified time frames
  • Medical conditions or histories that contraindicate contraceptive use according to CDC guidelines
  • Use of blood thinners or bleeding disorders
  • Use of drugs affecting hormone metabolism (P450 pathway inducers)
  • Inability to tolerate uterine sounding at screening
  • Frequent use of cannabis products or cigarettes without required washout periods

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

OHSU

Portland, Oregon, United States, 97239

Actively Recruiting

Loading map...

Research Team

W

Women's Health Research Unit Research Unit Department of OB/Gyn

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here